Please login to the form below

Not currently logged in
Email:
Password:

Aspen Pharmacare

This page shows the latest Aspen Pharmacare news and features for those working in and with pharma, biotech and healthcare.

Sandoz expands into Japan with €400m Aspen deal

Sandoz expands into Japan with €400m Aspen deal

The agreement will see Sandoz acquire the entirety of Aspen Global Incorporated’s (AGI) Japanese business division, which is a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. ... The proceeds Aspen gains from the transaction will be used

Latest news

  • EU starts investigation of Aspen's cancer drug pricing EU starts investigation of Aspen's cancer drug pricing

    Amid reports of price increases of several hundred per cent. Aspen Pharmacare is under investigation by the EU's competition authorities over its pricing of five cancer medicines, amid allegations of ... The five generic medicines - chlorambucil,

  • Publicis boosts South Africa presence Publicis boosts South Africa presence

    The agency has 80 staff and works with blue-chip clients such as Aspen Pharmacare, Tanqueray Gin and TOTAL.

  • GSK cashes in its stake in Africa's Aspen GSK cashes in its stake in Africa's Aspen

    Sells 28.2 million shares. GlaxoSmithKline (GSK) has agreed to reduce its stake in Aspen Pharmacare but says it will maintain a "close relationship" with the South African company. ... Aspen's shares dipped nearly 4 per cent on news of the divestment.

  • GSK sells Lucozade and Ribena for £1.35bn GSK sells Lucozade and Ribena for £1.35bn

    it offloaded several other products to to Aspen Pharmacare for £164m.

  • Tibotec HIV drug approved

    Aspen Pharmacare allowing them to manufacture, market and distribute the generic drug. ... Matrix and Hetero will have the rights to market the product in sub-Saharan Africa, certain developing countries and India, while Aspen will have rights to market

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    840. GSK / Aspen Pharmacare. Acquisition of assets. 2. Arixtra and Fraxiparine - anti-thrombotic agents.

  • Pharma deals during September 2013 Pharma deals during September 2013

    GSK also received $700m from the sale of two thrombosis drugs (Arixtra and Fraxiparine), to Aspen Pharmacare, South Africa's largest drug maker. ... This agreement provides Aspen with the opportunity to expand into Russia and the CIS.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

How Far Do You Want To Go?
Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...
"Fishbowl" Web Meeting for Internal POA Discussions: a Customer Story
Learn how our client successfully carried out a set of three virtual plan of action (POA) discussions, including one internal “Fishbowl” web meeting....
Whats the difference between patient engagement and patient experience?
We all talk a lot about patient engagement and patient experience. And sometimes, these terms are used interchangeably across the industry. But while they’re both important, they’re not the same....

Infographics